OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it has reached agreement to launch its own brands
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it has reached agreement to launch its own brands
OPTI shares have soared in July. Is it too late to get in, or is the company just getting started?
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Ascent Resources, Andrada
Launch of GoFigure products on Tmall China
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseanddiabetes, provides the following unaudited trading update ahead of the Group’s half year results for
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its wholly-owned subsidiary, ProBiotix Health Ltd, has extended
OptiBiotix Health plc, the life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and cardiovascular health, is now in a pivotal position.
We have been working in the background to improve the RNS announcement infrastructure liaising with the London Stock Exchange, we are happy to report our recent tests show us delivering
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
A look back at some of this week’s more interesting stories from London’s junior market. The big news in the markets this week has been the fall from grace of